RT info:eu-repo/semantics/article
T1 Influence of DNA mismatch repair (MMR) system in survival and response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC): Retrospective analysis
A1 Olivares Hernández, Alejandro
A1 Barco Morillo, Edel del
A1 Parra Pérez, Carmen
A1 Miramontes González, José Pablo
A1 Figuero Pérez, Luis
A1 Martín Gómez, Teresa
A1 Escala Cornejo, Roberto
A1 Bellido Hernández, Lorena
A1 González Sarmiento, Rogelio
A1 Cruz Hernández, Juan Jesús
A1 Ludeña de la Cruz, María Dolores
K1 DNA repair
K1 Immunotherapy
K1 Inmunoterapia
K1 Oncology
K1 Cancer research
K1 Immune checkpoint inhibitors (ICIs)
K1 Non small cell lung cancer
K1 Lungs - Cancer
K1 Pulmones - Cáncer
K1 Survival
K1 Supervivencia
K1 Retrospective analysis
K1 Genetics
K1 Genetica
K1 Molecular biology
K1 3207.13 Oncología
K1 2412 Inmunología
K1 2302.21 Biología Molecular
AB Mutations in the mismatch repair (MMR) system predict the response to immune checkpoint inhibitors (ICIs) like colon or gastric cancer. However, the MMR system’s involvement in non-small cell lung cancer (NSCLC) remains unknown. Addressing this issue will improve clinical guidelines in the case of mutations in the main genes of the MMR system (MLH1, MSH2, MSH6, and PMS2). This work retrospectively assessed the role that these gene mutations play in the response to and survival of ICIs in NSCLC. Patients with NSCLC treated with nivolumab as the second-line treatment in the University Hospital of Salamanca were enrolled in this study. Survival and response analyses were performed according to groups of MMR system gene expression (MMR expression present or deficiency) and other subgroups, such as toxicity. There was a statistically significant relationship between the best response obtained and the expression of the MMR system (p = 0.045). The presence of toxicity grade ≥ 3 was associated with the deficiency expression of MMR (dMMR/MSI-H) group (p = 0.022; odds ratio = 10.167, 95% confidence interval (CI) 1.669–61.919). A trend towards greater survival and response to ICIs was observed in NSCLC and dMMR. Assessing the genes in the MMR system involved in NSCLC is key to obtaining personalized immunotherapy treatments.
PB MDPI
SN 2227-9059
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/62058
UL https://uvadoc.uva.es/handle/10324/62058
LA eng
NO Biomedicines, 2022, Vol. 10, Nº. 2, 360
NO Producción Científica
DS UVaDOC
RD 25-nov-2024